Week in Review: BGI Genomics Completes $81 Million Chi-Next IPO

Deals and Financings -BGI Genomics completed a $81 million IPO on the Chi-Next exchange, surging 44% to the upper limit in first-day trading; -Shanghai Fosun Pharma will invest $73.5 million over nine years in a global innovative technology incubator; -ShangPharma Innovation, Inc. will collaborate with the University of California San Francisco by providing UCSF scientists with funding and other support for life science discoveries; -Imsight Medical, a Shenzhen-Hong Kong start-up, raised $3 million to develop an AI-assisted medical imaging analysis program; -Laekna, a China biotech, acquired global rights from Novartis for a prostate cancer treatment; -Novogene, a Beijing genomics services company, partnered with San Diego's Trovagene to validate Trovagene's urine collection and nucleic acid preservation device in China; Company News -Cochlear, an Australian cochlear implant company, announced plans to build a $37 million manufacturing facility in Chengdu; Trials and Approvals -Canada's Resverlogix and China's Hepalink have begun a Phase III trial in Taiwan of their partnered drug, apabetalone, in patients with cardiovascular disease and type 2 diabetes. Stock Symbols: (SHZ: 300676) (SHA: 600196; HK: 2196) (NSDQ: TROV) (ASE: COH) (TSX: RVX) (SHZ: 002399) Share this with colleagues: // //